CelLBxHealth PLC
DWV
Company Profile
Business description
CelLBxHealth PLC is engaged in the development and commercialisation of the Parsortix platform, with deployment in liquid biopsy - non-invasive cancer diagnostics. It operates in single segment of commercialisation of its Parsortix cell separation platform. It generates revenue from contracts with customers in the research-use market, with customers located across multiple geographic regions. Geographically it operates in UK, Europe, North America, and Rest of World with majority of revenue deriving from Europe and North America.
Contact
10 Nugent Road
The Surrey Research Park
Surrey
GuildfordGU2 7AF
GBRT: +44 1483343434
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
114
Stocks News & Analysis
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.30 | 38.70 | 0.43% |
| CAC 40 | 8,252.66 | 183.58 | -2.18% |
| DAX 40 | 24,897.45 | 567.80 | -2.23% |
| Dow JONES (US) | 52,340.03 | 585.12 | -1.11% |
| FTSE 100 | 10,489.04 | 176.84 | -1.66% |
| HKSE | 24,199.46 | 702.57 | 2.99% |
| NASDAQ | 25,768.04 | 50.65 | -0.20% |
| Nikkei 225 | 66,819.05 | 1,437.91 | -2.11% |
| NZX 50 Index | 13,665.18 | 97.61 | -0.71% |
| S&P 500 | 7,471.87 | 31.98 | -0.43% |
| S&P/ASX 200 | 8,785.10 | 47.50 | 0.54% |
| SSE Composite Index | 3,970.88 | 19.36 | -0.49% |